Replimune Group (NASDAQ:REPL) Shares Gap Down – What’s Next?

Posted by Stanley Muller on Jun 26th, 2026

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $11.13, but opened at $10.22. Replimune Group shares last traded at $10.8860, with a volume of 1,562,034 shares trading hands.

Analysts Set New Price Targets

A number of research firms have recently issued reports on REPL. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 price objective on the stock in a research note on Friday, May 29th. Jefferies Financial Group reiterated a “hold” rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Finally, Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. Seven investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $4.88.

View Our Latest Stock Report on REPL

Replimune Group Trading Down 1.6%

The firm has a market capitalization of $904.01 million, a price-to-earnings ratio of -3.19 and a beta of 0.91. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average price of $6.05 and a 200-day moving average price of $7.27.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of REPL. Braidwell LP lifted its stake in shares of Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares during the last quarter. Balyasny Asset Management L.P. boosted its holdings in Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after purchasing an additional 2,195,448 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Replimune Group during the fourth quarter worth $17,568,000. Erste Asset Management GmbH increased its position in Replimune Group by 13,597.5% during the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock worth $7,074,000 after buying an additional 1,618,100 shares during the last quarter. Finally, Commodore Capital LP bought a new position in Replimune Group during the fourth quarter valued at about $13,851,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.